

Special Issue

Advancing Pharmacogenetics in Pre-clinical Research: Unveiling New Avenues for Precision Medicine

Message from the Guest Editors

Pharmacogenetics tailors medical treatments based on individual genetic variations, optimizing drug response, efficacy and safety. Pre-clinical research forms the foundation for translating these findings into clinical practice. This issue aims to explore the latest discoveries in pharmacogenetics, with a focus on pre-clinical research and its impact on precision medicine. We welcome original research articles and reviews on various aspects of pharmacogenetics in pre-clinical research, including genetic variant identification, mechanistic insights, novel models and methodologies, integrating pharmacogenetic data in drug development and translational challenges. We invite your contributions to advance our understanding of pharmacogenetics and shape personalized therapeutics. Please, refer to the journal's submission guidelines for manuscript preparation and submission instructions. Contact us with any queries or for further information. Join us in uncovering new avenues for precision medicine!

Guest Editors

Dr. Miriam Saiz-Rodriguez

Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain

Dr. Shengying Qin

Bio-X Institutes, Shanghai Jiaotong University, Shanghai, China

Deadline for manuscript submissions

closed (31 December 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/193232

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).